Why the study?
HCM is an inherited cardiac disorder with MYBPC3 and PRKAG2 as known causal genes, requiring cellular models to investigate variant-specific pathological mechanisms.
The successful generation of these patient-specific iPSC lines provides a valuable in vitro model for studying the pathological mechanisms of hypertrophic cardiomyopathy associated with MYBPC3 and PRKAG2 variants.
Answers are grounded in this paper and cite their sources.
Patient-specific iPSC lines enable in vitro HCM mechanism studies; leaves open clinical translation pending validation.
Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disorder characterized by a thick left ventricular wall and an increased risk of arrhythmias, heart failure, and sudden cardiac death. The MYBPC3 and PRAKG2 are known causal genes for HCM. Here we generated two human-induced pluripotent stem cell lines from two HCM patients carrying two heterozygous mutations in MYBPC3 (c.459delC) and PRKAG2 (c.1703C > T). Both iPSC lines expressed pluripotent markers, had a normal karyotype, and were able to differentiate into three germ layers, making them potentially valuable tools for modeling HCM in vitro and investigating the pathological mechanisms related to these two variants.
No takes yet. Share an insight, caveat, or question.
Manhas et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: